ADVERTISEMENT



Google       
Call (866) 635-2689 for a free Personal Injury evaluation by attorney in your area.

Home -> Law Blog Directory -> Personal Injury Law Blogs -> Tennessee Law Blog

OR PHONE (866) 635-1838 for Bankruptcy Help, (866) 635-6190 for Divorce,
(866) 635-2689 for Personal Injury or (866) 635-9402 for Criminal Defense

Find a Local Lawyer

Bankruptcy (866) 635-1838
Divorce (866) 635-6190
Personal Injury (866) 635-2689
Criminal Defense (866) 635-9402

Bookmark

Personal Injury Law

: Tennessee Law Blog

Historic Qui Tam Settlement Whistleblowers to Share $102 Million for Revealing Drug Manufacturer Misconduct

ADVERTISEMENTS

Pzifer?s off-label marketing of their anti-inflammatory drug Bextra will cost the pharmaceutical company a record-breaking $2.3 billion, $102 million of which will be split by five qui tam relators (whistleblowers). This most recent whistleblower lawsuit is the fourth illegal marketing lawsuit Pzifer?s settled since 2002. Of the $2.3B, $1B is in civil penalties with the remaining $1.195B as the largest criminal fine in U.S. history. This settlement is part of a four-year federal investigation into the business practices of the world?s largest pharmaceutical company.

At issue, this and previous lawsuits against the drug company allege marketing Bextra for ?off-label,? or non FDA-approved, uses. In 1991, Bextra received FDA approval as a treatment for arthritis and menstrual cramps. In April 2005, Bextra was recalled after FDA officials received mounting evidence that the painkiller increased risks of heart attack, stroke, pulmonary embolism, and Stevens-Johnson Syndrome, a serious and sometimes fatal skin reaction.

During these nearly 14 years of distribution, Pfizer allegedly marketed the drug to doctors as a treatment for acute pain, a treatment the FDA never approved and one which required large doses of Bextra, an increase that would accordingly raise the health risks posed by Bextra. While it is not illegal for doctors to treat patients with drugs as they see fit, it is illegal for drug companies to market off-label uses.

Part of this illegal marketing included, according to the whistleblower lawsuit, kickbacks, perks, and incentives.

In addition to the fine, Pfizer must pledge to improve its corporate behavior, including marketing practices, as part of the settlement. This is the third such pledge Pfizer has made since 1999, signing such agreements in 2002 for Lipitor and in 2004 for Neurontin. The government has also accused Pfizer of illegally marketing the antipsychotic Geodon.

Because one of the parties defrauded by Bextra?s off-label marketing was the federal government, whistleblowers were eligible to take qui tam action and receive a portion of the funds from the government lawsuit. Qui tam lawsuits require a special knowledge of False Claims laws and should be pursued through an experienced whistleblower attorney, such as my colleagues at Higgins Firm.

For more information on qui tam lawsuits, explore my TN law firm?s employment law pages on False Claims Whistleblower / Qui Tam lawsuits.


Full post as published by Tennessee Law Blog on September 09, 2009 (boomark / email).

Bloggers, promote your law blog by nominating your blog for inclusion in USLaw.com's Law Blog Directory and RSS Reader. Benefits described.
Related Law Articles

Lawsuits and Settlements

Related Searches

























































































































US Law
#1 Online Legal Resource













Your Blog Subscriptions
Subscribe to blogs

10,000+ Law Job Listings
Lawyer . Police . Paralegal . Etc
Earn a law-related degree
Are you the author of this blog? Adding USLaw.com to your Blogroll increases relevance. You qualify to display a USLaw Network badge.
Suggest changes to this blog's description or nominate another for inclusion. Register for updates.


Practice Area
Zip Code:

Contact a Lawyer Now!






0.0212 secs (new cache)